Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | VCP | P55072 | 3/20 | 0.47 |
| ▸ | PLD2 | O14939 | 3/20 | 0.44 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311918 | 0.90 | KDM4E (0.61) | KDM4EHSD17B10CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1311144 | 0.89 | KDM4E (0.62) | KDM4EHSD17B10CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1311450 | 0.86 | KDM4E (0.49) | KDM4EHSD17B10CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1314901 | 0.86 | KDM4E (0.49) | KDM4EHSD17B10CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1312276 | 0.86 | KDM4E (0.47) | KDM4EHSD17B10CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1312444 | 0.85 | KDM4E (0.48) | KDM4EHSD17B10CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1311838 | 0.85 | KDM4E (0.48) | KDM4EHSD17B10CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1312282 | 0.82 | KDM4E (0.45) | KDM4EHSD17B10CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1312989 | 0.82 | KDM4E (0.56) | KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL1311762 | 0.81 | KDM4E (0.48) | KDM4EHSD17B10CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386546-B1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC (JP) | 2015-08-19 | — | — | EP | disclosed |
| EP-2386546-B1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC (JP) | 2015-08-19 | — | — | EP | disclosed |
| US-8252790-B2 | Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity | RAQUALIA PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252790-B2 | Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity | RAQUALIA PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| EP-2386546-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RaQualia Pharma Inc (JP) | 2011-11-16 | — | — | EP | disclosed |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-RE42840-E1 | Stool flushing device | TOTO, LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2010058858-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | ラクオリア創薬株式会社 (JP) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | HTR2B, HTR1B, HTR3B | KDM4E 3923/4885HSD17B10 1637/4885CHRNB2 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.